Patents by Inventor Iring Heisler
Iring Heisler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220002268Abstract: The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.Type: ApplicationFiled: April 18, 2019Publication date: January 6, 2022Inventors: Alexander ARLT, Werner HALLENBACH, Hans-Georg SCHWARZ, Martin FUESSLEIN, Heinz-Juergen WROBLOWSKY, Marc LINKA, Ulrich GOERGENS, Kerstin ILG, Ulrich EBBINGHAUS-KINTSCHER, Yolanda CANCHO GRANDE, Arunas Jonas DAMIJONAITIS, Andreas TURBERG, Iring HEISLER
-
Publication number: 20210386070Abstract: The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.Type: ApplicationFiled: April 18, 2019Publication date: December 16, 2021Inventors: Alexander ARLT, Werner HALLENBACH, Hans-Georg SCHWARZ, Martin FUESSLEN, Heinz-Juergen WROBLOWSKY, Estella VUSCATO ARSEQUELL, Marc LINKA, kerstin ILG, Arunas DAMIJONAITIS, Ulrich EBBINGHAUS-KINTSCHER, Ulrich GOERGENS, Yolanda CANCHO GRANDE, peter JESCHKE, Juachim TELSER, Iring HEISLER, Andreas TURBERG
-
Publication number: 20210380566Abstract: The present invention relates to novel compounds of general formula (I): with A being A1 or A2: and in which T, X, Y, Ro, R1, R10 and R11 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 23, 2019Publication date: December 9, 2021Inventors: Nils GRIEBENOW, Walter HUEBSCH, Hans-Georg SCHWARZ, Wei ZHUANG, Bernd ALIG, Adeline KEHLER, Daniel KULKE, Iring HEISLER, Thomas ILG
-
Patent number: 11077111Abstract: The present application relates to the use of fused heteroaromatic pyrrolidones for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals and to the use thereof for production of medicaments for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.Type: GrantFiled: October 15, 2018Date of Patent: August 3, 2021Assignee: Bayer Animal Health GmbHInventors: Nils Griebenow, Maria De Lourdes Mottier, Gerald Beddies, Jörg Cramer, Ulf Bömer, Iring Heisler
-
Publication number: 20210155608Abstract: The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.Type: ApplicationFiled: April 15, 2019Publication date: May 27, 2021Inventors: Alexander ARLT, Werner HALLENBACH, Hans-Georg SCHWARZ, Martin FUESSLEIN, Heinz-Juergen WROBLOWSKY, Marc LINKA, Ulrich GOERGENS, Kerstin ILG, Ulrich EBBINGHAUS-KINTSCHER, Yolanda CANCHO GRANDE, Arunas Jonas DAMIJONAITIS, Sascha EILMUS, Andreas TURBERG, Iring HEISLER
-
Publication number: 20210147387Abstract: The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.Type: ApplicationFiled: April 10, 2019Publication date: May 20, 2021Inventors: Alexander ARLT, Werner HALLENBACH, Hans-Georg SCHWARZ, Martin FUESSLEIN, Heinz-Juergen WROBLOWSKY, Marc LINKA, Sascha EILMUS, Kerstin ILG, Ulrich GOERGENS, Arunas Jonas DAMIJONAITIS, Yolanda CANCHO GRANDE, Ulrich EBBINGHAUS-KINTSCHER, Peter JESCHKE, Weijie HA, Iring HEISLER, Andreas TURBERG
-
Publication number: 20210139468Abstract: The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 7, 2019Publication date: May 13, 2021Inventors: Walter HÜBSCH, Nils GRIEBENOW, Hans-Georg SCHWARZ, Daniel KULKE, Claudia BÖHM, Kirsten BÖRNGEN, Bernd ALIG, Wei ZHUANG, Iring HEISLER, Thomas ILG, Johannes KÖBBERLING, Adeline KÖHLER, Niels LINDNER, Ulrich GÖRGENS, Claudia WELZ, Maike HINK
-
Publication number: 20200377614Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors.Type: ApplicationFiled: August 17, 2020Publication date: December 3, 2020Applicant: Bayer Intellectual Property GmbHInventors: Antje KAHNERT, Kerstin UNTERSCHEMMANN, Iring HEISLER, Charlotte Christine KOPITZ, Joachim SCHUHMACHER
-
Patent number: 10781263Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: GrantFiled: March 16, 2018Date of Patent: September 22, 2020Assignee: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
-
Publication number: 20200261461Abstract: The present application relates to the use of fused heteroaromatic pyrrolidones for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals and to the use thereof for production of medicaments for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.Type: ApplicationFiled: October 15, 2018Publication date: August 20, 2020Applicant: Bayer Animal Health GmbHInventors: Nils GRIEBENOW, Maria De Lourdes MOTTIER, Gerald BEDDIES, Jörg CRAMER, Ulf BÖMER, Iring HEISLER
-
Patent number: 10647779Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: GrantFiled: July 21, 2017Date of Patent: May 12, 2020Assignee: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Kopitz, Joachim Schuhmacher
-
Publication number: 20200131175Abstract: The present invention covers azaquinoline compounds of general formula (I), with A being (A1) or (A2), and in which T, R1, R2, R3, R4, R5, R6 and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 22, 2018Publication date: April 30, 2020Applicant: BAYER ANIMAL HEALTH GMBHInventors: Nils GRIEBENOW, Wei ZHUANG, Adeline KÖHLER, Daniel KULKE, Claudia BÖHM, Kirsten BÖRNGEN, Thomas ILG, Hans-Georg SCHWARZ, Werner HALLENBACH, Ulrich GÖRGENS, Walter HÜBSCH, Bernd ALIG, Iring HEISLER, Isa Jana Irina JANSSEN
-
Publication number: 20180201690Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: ApplicationFiled: March 16, 2018Publication date: July 19, 2018Applicant: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
-
Publication number: 20170327589Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: ApplicationFiled: July 21, 2017Publication date: November 16, 2017Applicant: Bayer Intellectual Property GmbHInventors: Antje KAHNERT, Kerstin UNTERSCHEMMANN, Iring HEISLER, Charlotte KOPITZ, Joachim SCHUMACHER
-
Publication number: 20170226081Abstract: The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: July 22, 2015Publication date: August 10, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Bernd BUCHMANN, Iring HEISLER, Thomas MÜLLER, Arwed CLEVE, Mélanie HÉROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
-
Publication number: 20170210738Abstract: The present invention relates to chemical compounds of formula (I) that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: July 22, 2015Publication date: July 27, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Bernd BUCHMANN, Iring HEISLER, Thomas MÜLLER, Arwed CLEVE, Melanie HEROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
-
Publication number: 20170037028Abstract: The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: December 16, 2014Publication date: February 9, 2017Inventors: Iring HEISLER, Thomas MÜLLER, Holger SIEBENEICHER, Bernd BUCHMANN, Arwed CLEVE, Judith GÜNTHER, Marcus KOPPITZ, Melanie HEROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
-
Publication number: 20160193359Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: February 24, 2016Publication date: July 7, 2016Applicant: SEATTLE GENETICS, INC.Inventors: Hans-Georg LERCHEN, Lars LINDEN, Sherif EL SHEIKH, Jörg WILLUDA, Charlotte C. KOPITZ, Joachim SCHUHMACHER, Simone GREVEN, Christoph MAHLERT, Beatrix STELTE-LUDWIG, Sven GOLFIER, Rudolf BEIER, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Sandra BRUDER, Heike PETRUL, Hannah Jörißen, Sandra BORKOWSKI
-
Publication number: 20150322160Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors.Type: ApplicationFiled: July 20, 2015Publication date: November 12, 2015Inventors: Antje KAHNERT, Kerstin BERHÖRSTER, Iring HEISLER, Charlotte KOPITZ, Joachim SCHUMACHER
-
Publication number: 20150246136Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.Type: ApplicationFiled: May 11, 2015Publication date: September 3, 2015Applicant: SEATTLE GENETICS, INC.Inventors: Hans-Georg LERCHEN, Lars LINDEN, Sherif El SHEIKH, Jörg WILLUDA, Charlotte C. KOPITZ, Joachim SCHUHMACHER, Simone GREVEN, Christoph MAHLERT, Beatrix STELTE-LUDWIG, Sven GOLFIER, Rudolf BEIER, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Sandra BRUDER, Heike PETRUL, Hannah JÖRISSEN, Sandra BORKOWSKI